|
Adult cases
|
|
1
|
AML-NS
|
NA
|
36
|
74
|
M
|
NA
|
NA
|
NA
|
Panani et al. [20]
|
Greece
|
|
2
|
AML-M4
|
47,XX, + 6[8/18]
|
1
|
50
|
F
|
NA
|
NA
|
NA
|
Testa et al. [21]
|
USA
|
|
3
|
AML-M5
|
47,XX,+6[58/58]
|
4
|
24
|
F
|
NA
|
NA
|
NA
|
Weh et al. [22]
|
Germany
|
|
4
|
AML-M2
|
47,XX,+6[2/7]
|
NA
|
81
|
M
|
NA
|
NA
|
NA
|
Chan et al. [23]
|
Hong Kong
|
|
5
|
AML-M2
|
47,XX,+6[3/8]
|
NA
|
NA
|
F
|
NA
|
NA
|
NA
|
Berger et al. [24]
|
France
|
|
6
|
AML (M2)
|
47,XY,+6[15/21]
|
> 1
|
55
|
M
|
NA
|
NA
|
NA
|
UKCCG [25]
|
U.K.
|
|
7
|
AML (M5a)
|
47,XX,+6[17/17]
|
> 15
|
55
|
M
|
NA
|
NA
|
NA
|
UKCCG [25]
|
U.K.
|
|
8
|
AML-NS
|
47,XX,+6[2/?]
|
22
|
37
|
F
|
NA
|
NA
|
NA
|
UKCCG [25]
|
U.K.
|
|
9
|
AML-M2
|
47,XX,+6[3/9]/46,XX[6/)9]
|
3
|
63
|
F
|
4.8
|
13.5
|
6
|
Jonveaux et al. [18]
|
France
|
|
10
|
AML-M2
|
47,XX,+6[17/19]/46,XX[2/19]
|
1+
|
28
|
F
|
4
|
11
|
53
|
Jonveaux et al. [18]
|
France
|
|
11
|
AML-M4
|
47,XX,+6[19/30]/46,XX[11/30]
|
22
|
66
|
F
|
2.6
|
8.1
|
51
|
Mohamed et al. [11]
|
USA
|
|
12
|
AML-M1
|
47,XX,+6[30/30]
|
1
|
74
|
M
|
29.4
|
9.3
|
26
|
Mohamed et al. [11]
|
USA
|
|
13
|
AML-M1
|
47,XY,+6[20/20]
|
4
|
22
|
M
|
4.4
|
12.5
|
238
|
Mohamed et al. [11]
|
USA
|
|
14
|
AML-M1
|
47,XY,+6[7/20]/46,XY[13/20]
|
10
|
40
|
M
|
86.5
|
11.1
|
63
|
Mohamed et al. [11]
|
USA
|
|
15
|
AML-MRC
|
47,XX,+6[39/40]/46,XX[1/40]
|
> 47
|
37
|
F
|
5.1
|
12.2
|
11
|
Mohamed et al. [11]
|
USA
|
|
16
|
AML-NS
|
47,XX, +6[8/23]/46,XX[15/23]
|
27
|
41
|
F
|
NA
|
NA
|
NA
|
De Souza et al. [26]
|
Brazil
|
|
17
|
AML-NS
|
47,XX,+6
|
NA
|
NA
|
F
|
NA
|
NA
|
NA
|
Kerndrup and Kjeldsen [27]
|
Denmark
|
|
18
|
AML-NS
|
47,XX,+6 [11]
|
NA
|
61
|
F
|
NA
|
NA
|
NA
|
Beyer et al. [28]
|
Switzerland
|
|
19
|
AML-M1
|
47,XX,+6[20]
|
23
|
51
|
M
|
20.77
|
13.5
|
4
|
Yu et al. [4]
|
South Korea
|
|
20
|
AML-M2
|
47,XX,+6[20]
|
> 58
|
25
|
F
|
82.94
|
8
|
109
|
Yu et al. [4]
|
South Korea
|
|
21
|
AML-M4
|
47,XX,+6[4/20]/46,XX,[16/20]
|
3
|
82
|
M
|
5.08
|
6.4
|
21
|
Yu et al. [4]
|
South Korea
|
|
22
|
AML-M7
|
47,XX,+6[12/20]/46,XX[8/20]
|
1
|
21
|
F
|
56.3
|
5.4
|
85
|
Gupta et al. [10]
|
India
|
|
23
|
AML-NS
|
47,XX,+6
|
1
|
50
|
F
|
NR
|
8.5
|
11
|
Aydin et al. [29]
|
Turkey
|
|
24
|
AML-M5
|
47,XY,+6
|
3
|
75
|
M
|
103.8
|
7.3
|
80
|
Manabe et al. [12]
|
Japan
|
|
Pediatric cases
|
|
25
|
AML-NS
|
47,XY,+6
|
NA
|
11
|
M
|
NA
|
NA
|
NA
|
Philip et al. [13]
|
Denmark
|
|
26
|
AML-NS
|
47,XX,+6[8]
|
27
|
8
|
F
|
99
|
NA
|
NA
|
Benedict et al. [14]
|
USA
|
|
27
|
AML-(M3)
|
47,XY,+6
|
> 7
|
8
|
M
|
NA
|
NA
|
NA
|
UKCCG [25]
|
U.K.
|
|
28
|
AML-M7
|
47,XX,+6[9/20]/46,XX[11/20]
|
NA
|
1
|
M
|
16.4
|
7.6
|
6
|
McCullough et al. [15]
|
Ireland
|
|
29
|
AML-NS
|
47,XX,+6
|
18
|
8
|
F
|
NA
|
NA
|
NA
|
Koh et al. [19]
|
South Korea
|
|
30
|
AML-M4
|
47,XX,+6[12/15]/46,XX[3/15]
|
1
|
14
|
M
|
244
|
5.7
|
52
|
Present report
| |